The vaccines have entered phase three clinical trials.
QUICK FACTS:
- Pharmaceutical giant Pfizer is entering its third phase of clinical trials for mRNA flu vaccines with similar technology to their COVID-19 vaccines.
- The clinical trials are said to evaluate what the risks to adults might be if they rook the vaccine as a way to define against the yearly flu virus.
- Pfizer has cited the “flexibility of mRNA technology and its rapid manufacturing,” claiming that it would create a “better strain matches in future years” and “rapid, large-scale manufacturing of vaccines.”
- This news comes as questions about potentially deadly side effects of the COVID-19 vaccines have been on the rise.
STATEMENT FROM PFIZER:
- The clinical trial will reportedly “evaluate the efficacy, safety, tolerability and immunogenicity of the company’s quadrivalent modified RNA (modRNA) influenza vaccine candidate in approximately 25,000 healthy U.S. adults,” according to a company press release.
- The company cited its “experience with RNA viruses and mRNA technology” in reference to its COVID-19 vaccines, claiming it had gained “an even deeper understanding of the opportunity to potentially provide more efficacious vaccines,” according to Annaliesa Anderson (PhD), Senior Vice President and Chief Scientific Officer, Vaccine Research and Development at the company.
- “We are excited to start the first Phase 3 efficacy study of an mRNA-based influenza vaccine that could potentially deliver an improved flu vaccine to help address the significant burden of this disease,” she continued.
BACKGROUND:
- Just weeks ago, journalists at The Epoch Times reported on a study that found “irrefutable proof of causality” between the mRNA vaccines and vascular and organ damage.
- A summary of the study by the publication indicated that the vaccines “travel throughout the body and accumulate in various organs.”
- The vaccines were also found to cause “Vaccine-induced inflammation [that] can cause grave organ damage, especially in vessels, sometimes with deadly outcomes.”
- As American Faith reported on Monday, breast milk from lactating mothers who received the vaccine was found to contain mRNA that would likely be passed to an infant.
